Philippe Cassier
Overview
Explore the profile of Philippe Cassier including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
52
Citations
1132
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dufresne A, Attignon V, Ferrari A, Tonon L, Boyault S, Tabone-Eglinger S, et al.
Cancer Med
. 2024 Mar;
13(7):e7115.
PMID: 38553950
Introduction: The objective was to determine the added value of comprehensive molecular profile by whole-exome and RNA sequencing (WES/RNA-Seq) in advanced and refractory cancer patients who had no molecular-based treatment...
2.
Ballinger M, Pattnaik S, Mundra P, Zaheed M, Rath E, Priestley P, et al.
Science
. 2023 Jan;
379(6629):253-260.
PMID: 36656928
Cancer genetics has to date focused on epithelial malignancies, identifying multiple histotype-specific pathways underlying cancer susceptibility. Sarcomas are rare malignancies predominantly derived from embryonic mesoderm. To identify pathways specific to...
3.
Gauduchon T, Vanacker H, Pissaloux D, Cassier P, Dufresne A, Karanian M, et al.
Front Oncol
. 2022 Nov;
12:1012527.
PMID: 36439507
Background: While great advances in clinical and pathological description of tenosynovial giant cell tumors (TGCT) have been made, TGCT molecular heterogeneity represents an ongoing challenge. The canonical oncogenic fusion is...
4.
Bertrand-Chapel A, Caligaris C, Fenouil T, Savary C, Aires S, Martel S, et al.
Commun Biol
. 2022 Oct;
5(1):1068.
PMID: 36207615
TGF-β signaling is involved in pancreatic ductal adenocarcinoma (PDAC) tumorigenesis, representing one of the four major pathways genetically altered in 100% of PDAC cases. TGF-β exerts complex and pleiotropic effects...
5.
Gomez-Roca C, Cassier P, Zamarin D, Machiels J, Perez Gracia J, Hodi F, et al.
J Immunother Cancer
. 2022 May;
10(5).
PMID: 35577503
Background: This phase 1b study (NCT02323191) evaluated the safety, antitumor activity, pharmacokinetics, and pharmacodynamics of colony-stimulating factor-1 receptor-blocking monoclonal antibody (mAb) emactuzumab in combination with the programmed cell death-1 ligand...
6.
Chvetzoff G, Girodet M, Despax J, Baudry V, Duranti J, Mastroianni B, et al.
BMJ Open
. 2022 Apr;
12(4):e060317.
PMID: 35459679
Introduction: A few studies have highlighted the potential synergy between early palliative care and inclusion in an early-phase clinical trial that may improve quality of life, reduce symptoms of exhaustion...
7.
Wang J, Martin-Romano P, Cassier P, Johnson M, Haura E, Lenox L, et al.
Oncologist
. 2022 Mar;
27(7):536-e553.
PMID: 35325211
Background: Patients with KRAS-mutant cancers have limited treatment options. Here we present a phase I study of JNJ-74699157, an oral, selective, covalent inhibitor of the KRAS G12C isoform, in patients...
8.
Benezech S, Saintigny P, Attignon V, Pissaloux D, Paindavoine S, Faure-Conter C, et al.
JCO Precis Oncol
. 2022 Jan;
4:785-795.
PMID: 35050753
Purpose: The Program to Establish the Genetic and Immunologic Profile of Patient's Tumor for All Types of Advanced Cancer study (ClinicalTrials.gov identifier: NCT01774409) analyzed the genome of refractory cancers to...
9.
Rowinski E, Magne N, Fayette J, Daguenet E, Racadot S, Pommier P, et al.
Head Neck
. 2021 Oct;
43(12):3899-3910.
PMID: 34643313
Background: Genome analysis could provide tools to assess predictive molecular biomarkers of radioresistance. Methods: Head and neck squamous cell carcinoma patients included in ProfiLER study and who underwent a curative...
10.
Machiels J, Gomez-Roca C, Michot J, Zamarin D, Mitchell T, Catala G, et al.
J Immunother Cancer
. 2020 Oct;
8(2).
PMID: 33097612
Background: This phase Ib study evaluated the safety, clinical activity, pharmacokinetics, and pharmacodynamics (PD) of emactuzumab (anti-colony stimulating factor 1 receptor monoclonal antibody (mAb)) in combination with selicrelumab (agonistic cluster...